OBI Pharma Enters Collaboration with GlyTech to Expand GlycOBI® Enabling Technologies ...
OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies ...
British chemicals found in Assad’s drug factories that funded regime
Firm SureChem, based in Suffolk, claims products were supplied in 2010 ‘for general laboratory use and are fairly ...
PharmiWeb14 天
Injectable Cytotoxic Drugs Market Set to Reach USD 38.2 Billion by 2034, growing at a CAGR ...
The injectable cytotoxic drugs market is a critical segment of the global oncology and chemotherapy treatment market. Cytotoxic drugs are used primarily in the treatment of various cancers, as they ...
Targeted Oncology14 天
Tisagenlecleucel Efficacy in R/R Follicular Lymphoma Sustained With 4-Year Update
Long-term data from the pivotal phase 3 ELARA trial showed durable efficacy with tisagenlecleucel in high-risk follicular ...
ascopubs.org29 天
Using Cure Models for Trial Analysis and Design
Randomized Controlled Trial of a Virtually Delivered Exercise and Stress Management Program to Improve Physical Performance of Hematopoietic Cell Transplant Survivors In the article that accompanies ...
ascopubs.org29 天
Using Cure Models for Trial Analysis and Design
Randomized Controlled Trial of a Virtually Delivered Exercise and Stress Management Program to Improve Physical Performance of Hematopoietic Cell Transplant Survivors The following represents ...
oncnursingnews1 个月
FDA OKs New Drug Label for Fludarabine Phosphate for CLL Treatment
1 Fludarabine Phosphate Injection is now approved for use as a component of a combination regimen for the treatment of adults with B-cell chronic lymphocytic leukemia (CLL); and for the treatment of ...